Compare HYLN & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYLN | AQST |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | United States |
| Employees | 113 | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 587.6M | 529.4M |
| IPO Year | 2019 | 2007 |
| Metric | HYLN | AQST |
|---|---|---|
| Price | $3.37 | $4.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $7.75 | ★ $9.33 |
| AVG Volume (30 Days) | 1.4M | ★ 2.0M |
| Earning Date | 11-10-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,475,000.00 | ★ $67,430,000.00 |
| Revenue This Year | $334.53 | $14.58 |
| Revenue Next Year | $139.40 | $32.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 130.28 | 0.77 |
| 52 Week Low | $1.56 | $2.94 |
| 52 Week High | $8.49 | $6.93 |
| Indicator | HYLN | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 45.54 | 44.31 |
| Support Level | $3.16 | $4.03 |
| Resistance Level | $4.62 | $4.35 |
| Average True Range (ATR) | 0.18 | 0.23 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 47.85 | 40.03 |
Hyliion Holdings Corp designs and develops power generators for stationary and mobile applications and provides R&D service. It provides solutions that enable clean, flexible, and affordable electricity production. The company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. In addition to stationary power solutions, it focuses on mobile applications, including vehicles and marine technologies. Its products and services include: KARNO Power Modules which is a modular, fully enclosed, fuel-agnostic and fully integrated power generating solution.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.